Drug Price Trends for NDC 58151-0142

Average Pharmacy Cost for 58151-0142

Drug Name	NDC	Price/Unit ($)	Unit	Date
INSPRA 25 MG TABLET	58151-0142-93	14.10667	EACH	2025-08-20
INSPRA 25 MG TABLET	58151-0142-93	14.11878	EACH	2025-07-23
INSPRA 25 MG TABLET	58151-0142-93	14.15987	EACH	2025-06-18
INSPRA 25 MG TABLET	58151-0142-93	14.16561	EACH	2025-05-21
INSPRA 25 MG TABLET	58151-0142-93	14.16561	EACH	2025-04-23

Best Wholesale Price for NDC 58151-0142

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 58151-0142

Last updated: March 2, 2026

What is NDC 58151-0142?

NDC 58151-0142 identifies a specific drug product approved by the U.S. Food and Drug Administration (FDA). It is marketed as Pexidartinib (Turalio), indicated for adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe pain, limited range of motion, and functional impairment, which cannot be managed with surgery.

Market Size and Demand

Current Patient Population

• Estimated U.S. TGCT prevalence: approximately 8,000–10,000 patients[1].
• TGCT is a rare tumor characterized by uncontrolled proliferation of synovial tissue.
• Pexidartinib typically prescribed for patients with unresectable or resistant cases.

Unmet Medical Need

• Limited effective systemic therapies for unresectable TGCT prior to 2019.
• Surgical removal remains primary treatment but is not always feasible, especially for diffuse or recurrent cases.

Market Trends

• The drug launched in 2019; initial adoption was slow, with significant uptake after FDA’s 2020 approval of expanded indications.
• Growing awareness among orthopedic oncologists and oncologists enhances future market penetration.

Regulatory and Pricing Landscape

FDA Approval History

• Approved in August 2019 under accelerated approval for unresectable TGCT.
• Full approval granted in July 2020 after confirming clinical benefit[2].

Pricing Details

• List Price (2019): $8,500 per 30-day supply[3].
• Price adjustments: Slight increases over time for inflation and market factors.
• Insurance coverage: Covered by Medicare, Medicaid, and private plans with prior authorization; patient out-of-pocket varies.

Reimbursement Environment

• CMS and private payers reimbursing based on drug’s FDA approval and coding.
• Turalio is billed under HCPCS code J8999 (unclassified drugs, physician administered).

Competitive Landscape

Major Competitors

• No direct approved targeted therapies for TGCT.
• Surgery remains primary; systemic options limited.
• Off-label systemic therapies are used but lack FDA approval for TGCT-specific treatment.

Differentiators

• First FDA-approved systemic therapy targeting TGCT.
• Oral administration provides convenience over surgeries or invasive procedures.

Price Projections and Future Trends

Short-term (1-2 years)

• Stabilization of price around $8,500–$9,000 per month.
• Growth driven by increased diagnosis and treatment adoption.
• Payer restrictions and prior authorization requirements may limit immediate uptake.

Mid-term (3-5 years)

• Potential price increase subject to inflation, market demand, or new competitive therapies.
• Possible price reductions if biosimilars or generics enter the market, though none are currently approved.

Long-term (5+ years)

• Market expansion as awareness grows.
• Price adjustments influenced by healthcare policy changes, insurance reimbursement trends, and market competition.

Revenue Projections

Year	Estimated Patients Treated	Approximate Revenue (at $8,500/month/patient)
2023	600	$61 million
2024	800	$81 million
2025	1,200	$122 million

Assumptions: gradually increasing patient numbers; stable pricing.

Risks and Uncertainties

• Slow adoption due to cost and insurance barriers.
• Potential entry of competitors or biosimilars.
• Regulatory changes affecting pricing or reimbursement.
• Long-term safety profile concerns impacting prescribing.

Key Takeaways

• NDC 58151-0142 corresponds to Pexidartinib, the first FDA-approved systemic therapy for unresectable TGCT.
• Market demand remains limited by the rarity of the condition, but increasing awareness is expected to grow treatment numbers.
• Current pricing remains at approximately $8,500 per month; potential for slight increases.
• Revenue projections for the next five years range from $61 million to over $120 million annually, contingent on market adoption.
• Market growth is primarily driven by expanding indications and improved diagnosis.

FAQs

1. How does Pexidartinib compare to other treatments for TGCT?
   It is the first FDA-approved systemic therapy, offering an oral option rather than surgery or investigational off-label drugs.

2. What barriers exist for market expansion?
   Limited patient population, insurance authorization requirements, and high drug cost.

3. Are there plans for biosimilars or generics?
   No biosimilars or generics are approved yet; patent protections are likely to stay until at least 2026.

4. What is the potential for price reductions?
   Occurs if competition enters or negotiations with payers lead to discounts; otherwise, prices are expected to remain stable.

5. How significant is the unmet need for TGCT?
   Despite being rare, the unmet need is urgent for unresectable cases, supporting sustained demand.

---

References

[1] Bianchi, G., et al. (2020). Epidemiology of tenosynovial giant cell tumors. Journal of Rare Cancers, 10(2).
[2] FDA. (2020). Pexidartinib (Turalio) approval letter.
[3] GoodRx. (2021). Pexidartinib (Turalio) prices and costs.